Browsing by Subject "Granulocyte colony-stimulating factor"
Now showing items 1-13 of 13
-
Article
Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study
(2000)Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...
-
Article
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support
(2000)Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema ...
-
Article
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes
(1998)Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group
(2001)Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...
-
Article
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
(2001)BACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. ...
-
Article
High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study
(1995)The delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of ...
-
Article
Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: A phase I dose-finding and pharmacokinetic study
(2004)5-Fluorouracil (5FU) and cisplatin are commonly used in the treatment of gastric cancer. Continuous 5FU appears to be more effective and less toxic than bolus administration, while increasing the dose intensity of cisplatin ...
-
Article
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer
(1994)50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...
-
Article
The neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy
(2004)BACKGROUND. Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated ...
-
Article
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
(2003)Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. ...
-
Article
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP
(2002)Introduction: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has ...
-
Article
Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin
(1998)Tropisetron is a novel selective antagonist of the type-3 serotonin (5- HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m2 has a high emetogenic ...
-
Article
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: A study of the Hellenic Cooperative Oncology Group
(1999)This trial was conducted by the Hellenic Cooperative Oncology Group to improve the responses and survival in small cell lung cancer with a good prognosis, using a weekly intensive chemotherapy with alternated non-cross- ...